🟡 60/100

Review before taking

  • Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 500mg is 14.3× the Tolerable Upper Intake Level (35mg)

The safety score is low because the 500mg dose of niacin is more than 14 times the recommended daily upper limit of 35mg.

Label Data

1 Tablet(s) Serving Size
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

500 mg (2500% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 14.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 500mg UL 35mg

Other Ingredients

Carnauba wax Vegetable Lubricant Croscarmellose Sodium

Label Claims — Verification

All Other
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Directions: One tablet one to four times daily, or more, as directed by a doctor.

⚠️ Warnings & Precautions

Tamper evident band around cap and seal on bottle. Do not use if either seal is broken or missing.

Keep out of reach of children.

Notice: Niacin may produce flushing, tingling, itching and feeling if warmth in certain individuals, which under normal continuous use will disappear. However, of conditions persist, consult a doctor.

Additional Information

Sold only for dispensing by a licensed health care professional.

This product has been packaged in a 3rd party inspected, GMP facility. (Good Manufacturing Practices)

Rev. E0213 Reorder No. 435

GMP 3rd party confirmed compliant

Science + Therapeutic potency = Results Since 1972

Formulated to release part of the niacin quickly, with the remainder being released over several hours.

Product Details

UPC / SKU 3 51821 00435 8
DSLD Entry Date 2017-02-24
Product Type Vitamin
Form Tablet or Pill
DSLD ID 71252
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →